Shrinking a spectrometer loses performance, but Rockley improved the signal
For generations, the dream of knowing one's body from the outside—without needles, without labs, without waiting—has lived at the edge of medicine's reach. Now, a British startup called Rockley Photonics, working quietly with Apple as its largest client, is miniaturizing a laboratory spectrometer down to a chip that could one day read glucose, blood pressure, and hydration from the wrist using light alone. The partnership surfaced in an SEC filing ahead of a $1.2 billion IPO, with commercial sensors potentially arriving in early 2022. Whether the technology fulfills its promise remains uncertain, but the signal is clear: the boundary between wearable and medical device is being redrawn.
- The longstanding gap between what a smartwatch can sense and what a doctor can measure is now the central engineering battleground for Apple and its partners.
- Rockley Photonics has shrunk a bench-sized spectrometer—normally a $10,000 laboratory instrument—into a chip small enough to sit inside a watch, a feat that required solving serious signal-to-noise problems at miniature scale.
- Apple's quiet move to become Rockley's largest customer, revealed only through an IPO filing, suggests the company is further along this path than any public announcement has indicated.
- Samsung, Zepp Health, LifeSignals, and Withings are all circling the same technology, signaling that non-invasive biometric sensing is becoming an industry-wide race rather than a single company's moonshot.
- The road to a wrist-worn glucose monitor still runs through regulatory uncertainty, real-world performance validation, and Apple's own internal calculus on whether the feature is ready for consumers.
If you've owned an Apple Watch, you've likely noticed what it cannot do: measure blood sugar. That gap may be narrowing. Apple has quietly become the largest customer of Rockley Photonics, a British startup engineering sensors capable of reading glucose noninvasively from the wrist using light.
Rockley's approach extends the same optical principle already inside the Apple Watch—bouncing infrared and visible light off blood vessels beneath the skin—but expands it dramatically. The company has miniaturized a laboratory spectrometer, a device that typically costs thousands of dollars and occupies a benchtop, down to a chip small enough for a smartwatch. That chip reads a far wider range of wavelengths, capturing data on glucose, blood pressure, hydration, and alcohol levels.
The engineering is genuinely difficult. Shrinking a spectrometer sacrifices light-gathering ability, but Rockley claims to have improved the signal-to-noise ratio to the point of medical usefulness. Two modules are in development: a basic version covering heart rate, oxygen, blood pressure, hydration, and temperature, and an advanced version adding glucose, lactate, carbon monoxide, and alcohol—the one Apple is reportedly pursuing for high-end devices.
The partnership emerged through an SEC filing as Rockley prepared for a $1.2 billion IPO, with both modules potentially reaching commercial launch in the first half of 2022. Samsung, Zepp Health, LifeSignals, and Withings are also working with the company, underscoring how broadly the industry is betting on this technology.
None of it is certain. The sensors may underperform. Regulatory barriers may prove too high. Apple may simply decide the moment isn't right. But the fact that Apple has committed to Rockley at this scale suggests something more than curiosity—it suggests a company that believes the wrist may soon tell us things about our bodies that once required a clinic.
If you've owned an Apple Watch, you've probably wondered why it can measure your heart rate and blood oxygen but not your blood sugar. That gap may be closing. Apple has quietly become the largest customer of Rockley Photonics, a British electronics startup building sensors that could do exactly that—measure glucose noninvasively from your wrist.
Rockley's approach builds on technology already in the Apple Watch. The current sensors use infrared and visible light, bouncing it off blood vessels and cells beneath the skin to calculate heart rate and oxygen levels. Red LEDs handle the oxygen measurement. Rockley is taking that same basic principle and expanding it dramatically. The company has miniaturized a laboratory spectrometer—a machine that typically sits on a bench and costs thousands of dollars—down to a chip small enough to fit in a smartwatch. That chip can detect light across a much wider range of wavelengths than current sensors, including infrared bands that reveal information about glucose, blood pressure, hydration, and alcohol levels in the blood.
The engineering challenge is real. Shrinking a spectrometer loses you performance and light-gathering ability. But Rockley has managed to improve the signal-to-noise ratio—the ratio of useful data to electronic noise—to a point where the readings become medically useful. The company is developing two versions: a basic module that measures heart rate, oxygen saturation, blood pressure, hydration, and core body temperature, and an advanced module that adds glucose, carbon monoxide, lactate, and alcohol detection. Apple is interested in the advanced version, which Rockley is positioning for high-end smartwatches.
The timeline matters. Rockley revealed this partnership in an SEC filing as the company prepared for a $1.2 billion initial public offering on the New York Stock Exchange. The company's roadmap suggests both modules could be ready for commercial launch in the first half of 2022. Other major tech and health companies are watching too—Samsung, Zepp Health, LifeSignals Group, and Withings are all actively working with Rockley on similar projects.
None of this is guaranteed. The technology could fail to perform as promised. Apple might decide the sensors aren't ready, or that the regulatory hurdles are too high, or that consumers don't actually want this feature badly enough to justify the engineering effort. But the fact that Apple has made Rockley its largest customer, and that the company is moving toward commercial production, suggests the company sees real promise. For anyone who has wanted their smartwatch to do more than count steps and measure heart rate, this is the kind of quiet signal that something bigger might be coming.
Citas Notables
Rockley has shrunk a bench-top spectrometer to the size of a chip, improving signal-to-noise ratio to make the data usable for capturing a wide range of biophysical and biochemical biomarkers— Rockley Photonics technical approach
La Conversación del Hearth Otra perspectiva de la historia
Why does this matter? We already have glucose monitors. Why does Apple need to put one on a watch?
Because existing glucose monitors require a finger prick or a sensor inserted under the skin. Noninvasive measurement from your wrist—just wearing it—changes the equation entirely. It becomes something you don't have to think about.
And Rockley can actually do this? They're not just talking about it?
They've miniaturized a spectrometer to chip size and improved the signal quality enough to make it work. That's real engineering. Whether it works *well enough* for medical use is still an open question, but they're far enough along that Apple made them their biggest customer.
Why would Apple care about blood sugar specifically?
Diabetes affects hundreds of millions of people. If you could monitor glucose continuously without needles, you'd have a product that solves a real problem for a huge market. It's not just a nice feature—it's a health tool.
So when could we actually see this in an Apple Watch?
Rockley's roadmap says first half of 2022 for commercial availability. But that's Rockley's timeline. Apple moves at its own pace. Even if the sensors are ready, there's regulatory approval to consider, and Apple will want to be certain it works before putting it in millions of watches.
What if it doesn't work?
Then we're back where we started. But the fact that Apple is betting on it suggests they've seen something promising in the lab.